Pulse Biosciences, Inc (PLSE) financial statements (2021 and earlier)

Company profile

Business Address 3957 POINT EDEN WAY
HAYWARD, CA 94545
State of Incorp. DE
Fiscal Year End December 31
SIC 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:1230381673443
Cash and cash equivalents12738871011
Short-term investments     2532
Other undisclosed cash, cash equivalents, and short-term investments 23 8   
Other undisclosed current assets101112012
Total current assets:22303916263645
Noncurrent Assets
Operating lease, right-of-use asset91010551 
Property, plant and equipment2333322
Intangible assets, net (including goodwill)7777788
Goodwill3333333
Intangible assets, net (excluding goodwill)4444555
Other noncurrent assets0001022
Other undisclosed noncurrent assets      1
Total noncurrent assets:19192015161312
TOTAL ASSETS:41505832424957
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7653443
Accounts payable2111222
Accrued liabilities5432222
Debt  00 0 
Other undisclosed current liabilities10    0
Total current liabilities:8653443
Noncurrent Liabilities
Long-term debt and lease obligation111111774 
Operating lease, liability111111774 
Other undisclosed noncurrent liabilities(11)(11)    4
Total noncurrent liabilities: 11117744
Total liabilities:181716101187
Stockholders' equity
Stockholders' equity attributable to parent23334222314150
Common stock0000000
Additional paid in capital195191188156153150147
Accumulated other comprehensive income (loss)(0)0 0000
Accumulated deficit(173)(159)(146)(135)(123)(109)(97)
Total stockholders' equity:23334222314150
TOTAL LIABILITIES AND EQUITY:41505832424957

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Revenues
(Net Investment Income)
0000000
Other undisclosed gross profit(1)   (1)  
Gross profit:(0)000(0)00
Operating expenses(14)(13)(11)(12)(14)(12)(12)
Other undisclosed operating income1   1  
Operating loss:(14)(13)(11)(12)(14)(12)(11)
Nonoperating expense
(Investment Income, Nonoperating)
(0)      
Other undisclosed income from continuing operations before equity method investments, income taxes0      
Loss from continuing operations before income taxes:(14)(13)(11)(12)(14)(12)(11)
Other undisclosed loss from continuing operations(0)      
Net loss:(14)(13)(11)(12)(14)(12)(11)
Other undisclosed net income attributable to parent0      
Net loss available to common stockholders, diluted:(14)(13)(11)(12)(14)(12)(11)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(14)(13)(11)(12)(14)(12)(11)
Comprehensive loss:(14)(13)(11)(12)(14)(12)(11)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent00(0)0(0)(0)0
Comprehensive loss, net of tax, attributable to parent:(14)(13)(11)(12)(14)(12)(11)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: